It is obvious that a screening of donors for the presence and levels of NAbs or antibodies blocking the RBD–ACE2 interaction will be very helpful to improve the efficacy of passive immunization strategies for the treatment of COVID-19, because one can select donors with high levels of NAbs for manufacturing the polyclonal antibody preparations (Figure 3). The gene discussed is ACE2; the disease is COVID-19.